Literature DB >> 19351865

Angiotensin II-induced cyclooxygenase 2 expression in rat aorta vascular smooth muscle cells does not require heterotrimeric G protein activation.

Thomas A Morinelli1, Ryan T Kendall, Louis M Luttrell, Linda P Walker, Michael E Ullian.   

Abstract

Angiotensin II (AngII) initiates cellular effects via its G protein-coupled angiotensin 1 (AT(1)) receptor (AT(1)R). Previously, we showed that AngII-induced expression of the prostanoid-producing enzyme cyclooxygenase 2 (COX-2) was dependent upon nuclear trafficking of activated AT(1)R. In the present study, mastoparan (an activator of G proteins), suramin (an inhibitor of G proteins), 1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122; a specific inhibitor of phospholipase C), and sarcosine(1)-Ile(4)-Ile(8)-AngII (SII-AngII; a G protein-independent AT(1)R agonist) were used to determine the involvement of G proteins and AT(1A)R trafficking in AngII-stimulated COX-2 protein expression in human embryonic kidney-293 cells stably expressing AT(1A)/green fluorescent protein receptors and cultured vascular smooth muscle cells, respectively. Mastoparan alone stimulated release of intracellular calcium and increased COX-2 expression. Preincubation with mastoparan inhibited AngII-induced calcium signaling without altering AngII-induced AT(1A)R trafficking, p42/44 extracellular signal-regulated kinase (ERK) activation, or COX-2 expression. Suramin or U73122 had no significant effect on their own; they did not inhibit AngII-induced AT(1A)R trafficking, p42/44 ERK activation, or COX-2 expression; but they did inhibit AngII-induced calcium responses. SII-AngII stimulated AT(1A)R trafficking and increased COX-2 protein expression without activating intracellular calcium release. These data suggest that G protein activation results in increased COX-2 protein expression, but AngII-induced COX-2 expression seems to occur independently of G protein activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351865     DOI: 10.1124/jpet.109.151829

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes.

Authors:  Pia Lindgren Jeppesen; Gitte Lund Christensen; Mikael Schneider; Anne Yaël Nossent; Hasse Brønnum Jensen; Ditte Caroline Andersen; Tilde Eskildsen; Steen Gammeltoft; Jakob Lerche Hansen; Søren Paludan Sheikh
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G protein-independent signaling network.

Authors:  Ryan T Kendall; Erik G Strungs; Saleh M Rachidi; Mi-Hye Lee; Hesham M El-Shewy; Deirdre K Luttrell; Michael G Janech; Louis M Luttrell
Journal:  J Biol Chem       Date:  2011-04-18       Impact factor: 5.157

Review 3.  Functional relevance of biased signaling at the angiotensin II type 1 receptor.

Authors:  Douglas G Tilley
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2011-06       Impact factor: 2.895

4.  Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II.

Authors:  Torrance Green; Jorge Rodriguez; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

5.  β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice.

Authors:  Darshini B Trivedi; Charles D Loftin; James Clark; Page Myers; Laura M DeGraff; Jennifer Cheng; Darryl C Zeldin; Robert Langenbach
Journal:  Circ Res       Date:  2013-03-22       Impact factor: 17.367

6.  Angiotensin II activates NF-κB through AT1A receptor recruitment of β-arrestin in cultured rat vascular smooth muscle cells.

Authors:  Thomas A Morinelli; Mi-Hye Lee; Ryan T Kendall; Louis M Luttrell; Linda P Walker; Michael E Ullian
Journal:  Am J Physiol Cell Physiol       Date:  2013-04-10       Impact factor: 4.249

Review 7.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.